Respiratory syncytial virus protein structure, function and implications for subunit vaccine development

Future Virology

Volumn 9, Issue 8, 2014, Pages 753-767

  McCarthy, Michael ^a   Villafana, Tonya ^a   Stillman, Elizabeth ^a,b   Esser, Mark T ^a  

^a MEDIMMUNE   (United States)

^b ES Consulting   (United States)

Author keywords

adjuvant; correlate of protection; neutralizing antibody; pre fusion F; respiratory syncytial virus; subunit vaccine

Indexed keywords

F PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN; RESPIRATORY SYNCYTIAL VIRUS PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AGED; EPIDEMIOLOGY; HUMAN; IMMUNOGENICITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTECTION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRION; VIROLOGY;

EID: 84908025230     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.14.60     Document Type: Review

References (111)

1. Blount RE Jr, Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Biol. Med. 92(3), 544-549 (1956).
2. Collins PL, Karron RA. Respiratory syncytial virus and metapneumovirus. In: Fields Virology (Volume 1). Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA, 1443-1475 (2013).
3. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162(1-2), 80-99 (2011).
4. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N. Engl. J. Med. 288(10), 498-505 (1973).
5. Brandt CD, Kim HW, Arrobio JO et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. 3. Composite analysis of eleven consecutive yearly epidemics. Am. J. Epidemiol. 98(5), 355-364 (1973).
6. Shay DK, Holman RC, Newman RD, Liu LL, Stout J W, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282(15), 1440-1446 (1999).
7. Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725), 1545-1555 (2010).
8. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859), 2095-2128 (2012).
9. Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360(6), 588-598 (2009).
10. Hall CB. Respiratory syncytial virus and parainfuenza virus. N. Engl. J. Med. 344(25), 1917-1928 (2001).
11. Zhou H, Thompson WW, Viboud CG et al. Hospitalizations associated with infuenza and respiratory syncytial virus in the United States, 1993-2008. Clin. Infect. Dis. 54(10), 1427-1436 (2012).
12. Bourgeois FT, Valim C, McAdam AJ, Mandl KD. Relative impact of infuenza and respiratory syncytial virus in young children. Pediatrics 124(6), e1072-e1080 (2009).
13. McClure DL, Kieke BA, Sundaram ME et al. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥ 50 years old. PLoS ONE (2014) (In Press).
14. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352 (17), 1749-1759 (2005).
15. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with infuenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003).
16. Falsey AR, McElhaney JE, Beran J et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe infuenza-like illness. J. Infect. Dis. 209 (12), 1873-1881 (2014).
17. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med. 300(10), 530-534 (1979).
18. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163 (4), 693-698 (1991).
19. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin. Infect. Dis. 33(6), 792-796 (2001).
20. Wagner DK, Graham BS, Wright PF et al. Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J. Clin. Microbiol. 24(2), 304-306 (1986).
21. Wagner DK, Muelenaer P, Henderson FW et al. Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after frst, second, and third infections. J. Clin. Microbiol. 27(3), 589-592 (1989).
22. Wagner DK, Nelson DL, Walsh EE, Reimer CB, Henderson FW, Murphy BR. Differential immunoglobulin G subclass antibody titers to respiratory syncytial virus F and G glycoproteins in adults. J. Clin. Microbiol. 25(4), 748-750 (1987).
23. Murphy BR, Graham BS, Prince GA et al. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J. Clin. Microbiol. 23(6), 1009-1014 (1986).
24. Stensballe LG, Ravn H, Kristensen K et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. J. Allergy Clin. Immunol. 123(2), 398-403 (2009).
25. Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J. Infect. Dis. 177(2), 463-466 (1998).
26. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen W P. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21(24), 3479-3482 (2003).
27. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J. Infect. Dis. 189(2), 233-238 (2004).
28. Luchsinger V, Piedra PA, Ruiz M et al. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin. Infect. Dis. 54(7), 905-912 (2012).
29. Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res. 63 (3), 191-196 (2004).
30. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99(1), 93-99 (1997).
31. Siber GR, Leszcynski J, Pena-Cruz V et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization a s say. J. Infect. Dis. 165(3), 456-463 (1992)
32. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102(3), 531-537 (1998).
33. Carbonell-Estrany X, Simoes EA, Dagan R et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125(1), e35-e51 (2010).
34. Zaman K, Roy E, Arifeen SE et al. Effectiveness of maternal infuenza immunization in mothers and infants. N. Engl. J. Med. 359 (15), 1555-1564 (2008).
35. Advisory Committee on Immunization Practices (ACIP). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant <12 months of age (2011). www.cdc.gov/mmwr/preview/mmwrhtml/mm6041a4.htm
36. Blencowe H, Lawn J, Vandelaer J, Roper M, Cousens S. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int. J. Epidemiol. 39(Suppl. 1), i102-i109 (2010).
37. Eick A, Karron R, Shaw J et al. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease. Pediatr. Infect. Dis. J. 27(3), 207-212 (2008).
38. Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S. Maternal antibody and respiratory syncytial virus infection in infancy. J. Med. Virol. 7(4), 263-271 (1981).
39. Roca A, Abacassamo F, Loscertales MP et al. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. J. Med. Virol. 67(4), 616-623 (2002).
40. Glezen W P, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 98(5), 708-715 (1981).
41. Novavax. Novavax announces positive top-line data from dose-confrmatory Phase 2 clinical trial of its RSV vaccine candidate in women of childbearing age (2014). www.novavax.com/download/releases/NVAX%20M202%20Data%20 Announcement%20PR%202014-04-28%20 FINAL%20for%20Global%20Newswire.pdf
42. Robbie GJ, Criste R, Dall'acqua WF et al. A novel investigational Fc-modifed humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob. Agents Chemother. 57(12), 6147-6153 (2013).
43. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J. Med. Virol. 78(11), 1493-1497 (2006).
44. Terrosi C, Di Genova G, Martorelli B, Valentini M, Cusi MG. Humoral immunity to respiratory syncytial virus in young and elderly adults. Epidemiol. Infect. 137(12), 1684-1686 (2009).
45. Falsey AR, Walsh EE, Looney RJ et al. Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J. Med. Virol. 59(2), 221-226 (1999).
46. Walsh EE, Falsey AR. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J. Med. Virol. 73(2), 295-299 (2004).
47. Connors M, Collins PL, Firestone CY, Murphy BR. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65(3), 1634-1637 (1991).
48. Teng MN, Collins PL. The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for effcient viral infection in vitro or in vivo. J. Virol. 76(12), 6164-6171 (2002).
49. Sullender WM, Mufson MA, Prince GA, Anderson LJ, Wertz GW. Antigenic and genetic diversity among the attachment proteins of group A respiratory syncytial viruses that have caused repeat infections in children. J. Infect. Dis. 178(4), 925-932 (1998).
50. Sullender WM, Mufson MA, Anderson LJ, Wertz GW. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J. Virol. 65(10), 5425-5434 (1991).
51. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63(7), 2941-2950 (1989).
52. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2(8), 732-738 (2001).
53. Hendricks DA, McIntosh K, Patterson JL. Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J. Virol. 62(7), 2228-2233 (1988).
54. Bukreyev A, Yang L, Fricke J et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82(24), 12191-12204 (2008).
55. Jorquera PA, Choi Y, Oakley KE et al. Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS ONE 8(9), e74905 (2013).
56. Zhang W, Choi Y, Haynes LM et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary infammation and virus replication in mice. J. Virol. 84(2), 1148-1157 (2010).
57. Routledge EG, Willcocks MM, Samson AC et al. The purifcation of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice. J. Gen. Virol. 69(Pt 2), 293-303 (1988).
58. Murphy BR, Sotnikov A, Paradiso PR et al. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7(6), 533-540 (1989).
59. Prince GA, Capiau C, Deschamps M et al. Effcacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J. Virol. 74(22), 10287-10292 (2000).
60. Power UF, Nguyen TN, Rietveld E et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184(11), 1456-1460 (2001).
61. Falsey AR, Walsh EE, Capellan J et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines-nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with infuenza vaccine to high-risk elderly individuals. J. Infect. Dis. 198(9), 1317-1326 (2008).
62. Gonzalez-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B et al. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc. Natl Acad. Sci. USA 98(17), 9859-9864 (2001).
63. Zimmer G, Budz L, Herrler G. Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J. Biol. Chem. 276(34), 31642-31650 (2001).
64. Collins PL, Mottet G. Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. J. Gen. Virol. 72(Pt 12), 3095-3101 (1991).
65. McLellan JS, Chen M, Leung S et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specifc neutralizing antibody. Science 340 (6136), 1113-1117 (2013).
66. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85 (15), 7788-7796 (2011).
67. Swanson KA, Settembre EC, Shaw CA et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl Acad. Sci. USA 108(23), 9619-9624 (2011).
68. Chaiwatpongsakorn S, Epand RF, Collins PL, Epand RM, Peeples ME. Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer. J. Virol. 85(8), 3968-3977 (2011).
69. Kwakkenbos MJ, Diehl SA, Yasuda E et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16(1), 123-128 (2010).
70. Arbiza J, Taylor G, Lopez JA et al. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J. Gen. Virol. 73(Pt 9), 2225-2234 (1992).
71. Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J. Virol. 63(2), 925-932 (1989).
72. Lopez JA, Bustos R, Orvell C et al. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J. Virol. 72(8), 6922-6928 (1998).
73. Zhu Q, McAuliffe JM, Patel NK et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J. Infect. Dis. 203(5), 674-682 (2011).
74. Magro M, Mas V, Chappell K et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc. Natl Acad. Sci. USA 109(8), 3089-3094 (2012).
75. Plotkin SL, Plotkin SA. A short history of vaccination. In: Vaccines. Plotkin S, Orenstein W, Offt P (Eds). Saunders, PA, USA, 1-16 (2008).
76. US Food and Drug Administration. Complete list of vaccines licensed for immunization and distribution in the US (2014) www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833
77. McLellan JS, Correia BE, Chen M et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J. Mol. Biol. 409(5), 853-866 (2011).
78. Correia BE, Bates JT, Loomis RJ et al. Proof of principle for epitope-focused vaccine design. Nature 507(7491), 201-206 (2014).
79. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purifed fusion protein-2 vaccine in pregnant women. Vaccine 21(24), 3465-3467 (2003).
80. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14 (13), 1214-1218 (1996).
81. Piedra PA, Cron SG, Jewell A et al. Immunogenicity of a new purifed fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fbrosis. Vaccine 21(19-20), 2448-2460 (2003).
82. Glenn GM, Smith G, Fries L et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 31(3), 524-32 (2012).
83. McLellan JS, Chen M, Joyce MG et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342(6158), 592-598 (2013).
84. GlaxoSmithKline. NCT01905215 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines (2014). www.clinicaltrials.gov/show/NCT01905215
85. Einstein MH, Baron M, Levin MJ et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum. Vaccin. 7(12), 1343-1358 (2011).
86. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat. Med. 19(12), 1597-1608 (2013).
87. Cherukuri A, Stokes KL, Patton K et al. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun. Ageing 9(1), 21 (2012).
88. Kim H W, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89(4), 422-434 (1969).
89. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, 3rd, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68(8), 5321-5325 (1994).
90. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary infammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70(5), 2852-2860 (1996).
91. Geevarghese B, Weinberg A. Cell-mediated immune responses to respiratory syncytial virus infection: magnitude, kinetics, and correlates with morbidity and age. Hum. Vaccin. Immunother. 10(4), 27908 (2014).
92. Bendelja K, Gagro A, Bace A et al. Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine fow cytometry. Clin. Exp. Immunol. 121(2), 332-338 (2000).
93. Roman M, Calhoun WJ, Hinton KL et al. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am. J. Respir. Crit. Care Med. 156(1), 190-195 (1997).
94. Kristjansson S, Bjarnarson SP, Wennergren G et al. Respiratory syncytial virus and other respiratory viruses during the frst 3 months of life promote a local TH2-like response. J. Allergy Clin. Immunol. 116 (4), 805-811 (2005).
95. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr. Opin. Immunol. 22(3), 411-416 (2010).
96. RTS, S Clinical Trials Partnership; Agnandji ST, Lell B, Fernandes JF et al. A Phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367(24), 2284-2295 (2012).
97. Abdulla S, Salim N, Machera F et al. Randomized, controlled trial of the long term safety, immunogenicity and effcacy of RTS, S/AS02(D) malaria vaccine in infants living in a malaria-endemic region. Malar. J. 12, 11 (2013).
98. Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev. Vaccines 12(7), 747-758 (2013).
99. Cherukuri A, Patton K, Gasser RA Jr et al. Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin. Vaccine Immunol. 20(2), 239-247 (2013).
100. + memory T cell responses in elderly persons. J. Infect. Dis. 191(10), 1710-1718 (2005).
101. Looney RJ, Falsey AR, Walsh E, Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J. Infect. Dis. 185(5), 682-685 (2002).
102. Cusi MG, Martorelli B, Di Genova G, Terrosi C, Campoccia G, Correale P. Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects. Immun. Ageing 7, 14 (2010).
103. Begona Ruiz-Arguello M, Gonzalez-Reyes L, Calder LJ et al. Effect of proteolytic processing at two distinct sites on shape and aggregation of an anchorless fusion protein of human respiratory syncytial virus and fate of the intervening segment. Virology 298(2), 317-326 (2002).
104. ® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization. Vaccine 29(45), 7936-7941 (2011).
105. Shank-Retzlaff M, Wang F, Morley T et al. Correlation between mouse potency and in vitro relative potency for human papillomavirus type 16 virus-like particles and Gardasil vaccine samples. Hum. Vaccin. 1(5), 191-197 (2005).
106. Shank-Retzlaff ML, Zhao Q, Anderson C et al. Evaluation of the thermal stability of Gardasil. Hum. Vaccin. 2(4), 147-154 (2006).
107. Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 315 (7115), 1060-1064 (1997).
108. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 31(Suppl. 2), B209-B215 (2013).
109. Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging 22(7), 577-587 (2005).
110. Mullooly JP, Bridges CB, Thompson WW et al. Infuenza-and RSV-associated hospitalizations among adults. Vaccine 25(5), 846-855 (2007).
111. MedImmune LLC. A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults (2014). www.clinicaltrials.gov/show/NCT02115815